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ABSTRACT 
Recombinant Human Erythropoietin drugs are known as erythropoietin stimulating agents which stimulate the bone marrow to produce 
more red blood cells in the body. It is used an antianemic in the treatment of renal anemia and chemotherapy induced anemia. It also use in 
treatment of HIV, cerebral malaria and neurological disease like schizophrenia. The recombinant human erythropoietin dosage form currently 
available in the market is parenteral dosage form that is ready for injection liquid vial (syringe), which is usually administered 2-3 times weekly. 
To achieve a therapeutic effect of parenterally administered EPO, cumulative doses are required that significantly exceed levels of endogenous 
EPO. These high serum levels result in prolonged circulation times of EPO and unspecific binding to non-targeted tissue, which may lead to 
severe undesired side effects i.e. growth of tumor and also increased risk of death. By using the nanotechnology, side effects and toxicity related 
to high dose of erythropoietin should be reduces and prolong drug release. this will achieve by reducing administration frequency and lowering 
dosage of erythropoietin. 
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INTRODUCTION 
Recombinant human erythropoietin (rHu EPO) is a 40% 
glycosylated protein hormone containing 165 amino acids. It 
is produced by the peritubular capillary endothelial cells in 
the kidney with a small amount being produced in the liver. 
EPO can be produced biosynthetically using recombinant 
DNA technology. Recombinant DNA technology has used to 
develop the synthetic forms of erythropoietin such as 
epoetin alfa, darbepoetin alfa, epoetin beta, epoetin delta, 
epoetin omega, and among the others.  
EPO is considered as the world’s best-selling drug with 
annual sales in the range 10–15 billion USD per year and it is 
currently used to help about 5% of the world population 
with renal failure and anemia. 1   The global EPO drugs 
market is thus driven by increasing number of patients 
suffering from anemic condition induced due to cancer, HIV 
and ESRD treatment. Favorable reimbursements and 
increasing commercialization of EPO biosimilars the global 
Erythropoietin drugs market would reach $11.9 billion by 
2020, registering CAGR of 9.7% during 2014-2020. 
 
 
Uses of Erythropoietin: 2-3   
1) The main function of erythropoietin (EPO) is the 
regulation of erythropoiesis which is a long-term 
adaptation to boost O2-carrying capacity by increasing 
the number of RBCs and thus the haemoglobin 
concentration. 
2) These erythropoietin (EPO) drugs are used for treatment 
of chemotherapy-induced anemia; anemia is a common 
side-effect occurring due to chemotherapy of End Stage 
Renal Diseases (ESRD) 
3) Erythropoietin (EPO) is used for treatment of cancer and 
HIV.  
4) EPO has been shown to also help certain neurological 
disease like schizophrenia. 
5) Research has also suggested that EPO improves the 
survival rate for children suffering from cerebral 
malaria, which is caused by malaria parasite’s blocking 
blood vessels in brain. 
6) The most common use in people with anemia associated 
with abnormal function of the kidney.  
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GASTROINTESTINAL HURDLE IN ERYTHROPOIETIN 
ORAL DRUG DELIVERY 
The administration of erythropoietin by the oral route has 
been the goal of many researchers. However, the oral 
bioavailability of erythropoietin is very poor. 
Macromolecular proteins normally cannot cross the 
intestinal epithelium. They will instead be degraded in the 
gastrointestinal tract before absorption4. Three main 
obstacles of erythropoietin oral delivery need to be 
considered:  
1. Enzymatic barrier: The gastrointestinal tract has a variety 
of enzymatic barriers for erythropoietin oral delivery. The 
erythropoietin can be degraded by intracellular enzymes 
(e.g., cathepsins), bacterial flora in the mucus layer and in the 
epithelial cells of the intestine, and proteolytic enzymes in 
the stomach and in the intestinal lumen (e.g., pepsin, trypsin, 
and chymotrypsin) at the brush border membrane (e.g., 
endopeptidases). These enzymes denature protein drugs. 
Enzyme inhibitors can slow the erythropoietin degradation 
rate and increase the erythropoietin that is available for 
absorption. Sodium cholate and aprotinin reportedly act as 
enzyme inhibitors and improve protein absorption in rats 5.  
2. Physiological barrier: The epithelial cells of the 
gastrointestinal tract are tightly bound by tight junctions 
(i.e., the zonulae occludentes) in which the outer surface of 
the intestinal epithelium is coated by mucus and glycocalyx 
layers, and thus inhibits the passage of erythropoietin and its 
subsequent absorption6. Absorption may be enhanced by 
using absorption enhancers such as bile salts, trisodium 
citrates, EDTA, labrasol, and polymeric materials (e.g., 
chitosan), which help to open the tight junctions of the 
intestinal epithelium 5, 7, 8. 
3. Physicochemical properties of erythropoietin: The pore 
radius of the intestinal mucosa ranges 7e15A° which is an 
important barrier for macromolecular erythropoietin 
translocation. Temperature, solvents, and additives may 
disrupt the primary amino acid sequence and tertiary 
structure of protein. The alteration in the functional moiety 
or native charge of erythropoietin has an impact on its 
intestinal transport. At physiological pH, the carboxylic and 
amino groups of erythropoietin are entirely ionized, which 
results in a zwitterionic configuration. It is likely to preclude 
erythropoietin absorption from transcellular diffusion, 
unless the charges are neutralized through ion pairs 9. The 
large molecular size of erythropoietin nevertheless remains 
an obstacle to its absorption. Modification of erythropoietin 
chemical structure against possible enzymatic degradation is 
an approach to raise its bioavailability. A diacyl derivative of 
some protein drug has been shown to maintain biological 
activity and to increase intestinal absorption of some protein 
drug 10.  
DELIVERY SYSTEM FOR ERYTHROPOIETIN ORAL 
DELIVERY 
Nanoparticles: Nanotechnology is a rapidly expanding field, 
encompassing the development of man-made materials in 
the 5-200 nanometer size range. The nanotechnology 
revolution has begun and shows enormous promise in the 
field of drug delivery. Nanotechnology has the potential to 
improve patient quality of life through decreased 
administrations due to longer drug release profiles and 
decreased side-effects due to reduced concentrations of toxic 
medications and targeted delivery. The ultimate drug 
delivery system that provides a universal platform for 
diagnosis, imaging and therapeutic treatment is another lofty 
goal that may be achieved through the application of 
nanotechnology. Based on the literature review of 
nanotechnology in drug delivery it was decided to proceed 
with the intention of developing a nanoparticle drug delivery 
system for the encapsulation and controlled release of rHu-
EPO. Polymeric nanoparticles are selected as the most 
suitable due to their biocompatibility and non-toxic nature.11 
The bioavailability of orally delivered drugs is influenced by 
the physico-chemical properties of the drugs (i.e. solubility, 
pKa, size, etc.). Absorption of drug molecules depends on the 
particles in gastrointestinal tract (GIT) which occurs through 
various sites and depending upon their size. Particles size 
with 1 µm diameter are absorbed via phagocytosis by 
intestinal macrophages while particles <10 µm in diameter 
are transported through Peyer’s patches (lymphatic islands 
present on GIT). Nanoparticles (<200 nm) are absorbed 
through endocytosis by enterocytes.12 The efflux 
transporters such as P-glycoprotein (Pgp) and enzymes, 
expressed on enterocytes surface, also render the low 
systemic bioavailability of drugs affecting the absorption and 
excretion of drugs.13 Nanotechnology reveals the application 
of size scale complex systems in various fields due to their 
unique properties.14,15 One of the extensively studied areas 
of nanotechnology is delivering systems for the active 
ingredient of the medicine. Effective nanomedicine must be 
stable, biodegradable, non-toxic, non-inflammatory, non-
thrombogenic, nonimmunogenic and should escape by 
reticuloendothelial system.16,17 It has been proved 
experimentally that, for therapeutic and imaging 
applications, nanoparticles may range from 2 to 1000 nm 
should be applicable to different molecules such as small 
drugs, proteins, vaccines or nucleic acids. 18, 19  
APPROACHES FOR NANO PARTICULATE DRUG 
DELIVERY SYSTEM FOR ERYTHROPOIETIN 
Nanocarriers have immense potential for the effective oral 
delivery of erythropoietin. Designing nanocarriers to 
improve erythropoietin gastrointestinal absorption may be 
achieved via modifying the polymer or nanoparticle surface 
property and applying an enteric coating onto the 
nanoparticles. These can be combined with enzyme 
inhibitors or absorption enhancers, as previously mentioned 
20.  
1. Polymeric nanocarrier approach: The polymeric 
nanoparticle is an approach to improve erythropoietin 
absorption from the gastrointestinal tract. Synthetic or 
natural polymeric materials modulate erythropoietin release 
and consequent pharmacological activity. Erythropoietin-
loaded nanoparticles, which are prepared by using 
biodegradable polymers such as Chitosan, poly (lactide-co-
glycolide), poly anhydride, and poly alkyl cyanoacrylate are 
absorbed from the intestinal epithelial cells and transport 
erythropoietin through the intestinal mucosa20. 
Incorporating erythropoietin in polymeric nanoparticle 
having the certain benefit like 
 The drug incorporated is protected from biochemical 
degradation. 
 Targeted delivery through enhanced permeability and 
retention. 
 Extending in vivo half-life. 
 Providing prolonged drug release; augmenting drug 
efficacy. 
 Reducing side effects. 
 Reducing administration frequency and lowering drug 
dosage. 
 Enhance therapeutic effectiveness without frequent 
administration. 
 Avoid poor patient compliance  
 Reduction of drug toxicity & side effects. 
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2. Enteric coating approach: The enteric coating technique 
has been applied to erythropoietin oral delivery in which the 
enteric coating polymers possess a pH dependent property 
[21]. Polyacrylic polymers (e.g., Eudragit L100-55 and 
Eudragit S100) and cellulosic polymers (e.g., Hydroxy propyl 
methyl cellulose phthalate) have been widely used for this 
purpose 20, 21. The increase in erythropoietin bioavailability 
is achieved by filling the freeze-dried chitosan/ poly (g-
glutamic acid) (CS/g-PGA) nanoparticles in enteric coated 
capsules 22. The enteric-coated capsules protect the 
erythropoietin-loaded nanoparticles from acidic gastric fluid 
and rapidly liberate erythropoietin in the proximal segment 
of the small intestine. Thus, the absorption of erythropoietin 
into systemic circulation is improved and the relative 
bioavailability of erythropoietin is increased. 
3. Enzyme inhibitor approach: Erythropoietin, which is a 
protein, is easily digested and inactivated by digestive 
enzymes in the stomach after oral administration. Different 
protease inhibitors are administered along with the 
nanoparticles to inhibit the activity of these enzymes 24. 
Radwan and Aboul-Enein23 report that the oral 
administration of insulin (Protein drug) -loaded 
poly(ethylcyanoacrylate) nanoparticles in the presence of 
protease inhibitors (e.g., glycerrizin, capric acid, deoxycholic 
acid, hydroxypropyl-bcyclodextrin, and aprotinin) efficiently 
reduces and maintains glucose level < 200 mg/dL (i.e., the 
normal glucose level after a meal). Another approach to 
inhibit protease activity is by use of cationic metal chelating 
agents such as diethyl enetriamine penta acetic acid 
(DTPA)24. The addition of the complexing agent DTPA in 
insulin nanoparticles demonstrates a substantial protective 
effect against intestinal proteases in which the DTPA binds to 
cofactors [e.g., calcium (Ca2þ) and zinc (Zn2þ)] of the 
enzyme system and cause structural alterations and the loss 
of enzymatic activity. 
4. Permeation enhancers approach: The absorption of 
protein drug from the gastrointestinal tract is improved by 
the coadministration of permeation enhancers that widen 
the intercellular junction (e.g., paracellular pathway) and/or 
perturbate the membrane phospholipids (e.g., transcellular 
pathway) 25. Permeation enhancers which include fatty 
acids, surfactants, Ca2þ-chelating agents, and zonula 
occludens toxindare incorporated in the formulations. 
Another aspect is to conjugate with L-valine amino acid or 
any legand which are reported to improve the transport of 
protein drug across the epithelium cell of intestine. 26 
METHODS OF PREPARATION FOR NANOPARTICLES 
27, 28 
1. Emulsion Solvent Evaporation Method: This method is 
use most frequently used methods for the preparation of 
nanoparticles. Emulsification solvent evaporation method 
includes two steps. First step involve emulsification of the 
polymer solution into an aqueous phase. In the second step 
polymer solvent is evaporated, and polymer precipitation as 
nanospheres. Nanoparticles are collected by using 
ultracentrifugation process.  
 
After centrifugation residue wash with distilled water. Size of 
nanoparticles can be control by adjusting the stirring speed, 
type and amount of dispersing agents, temperature, viscosity 
of organic and aqueous phases. 
2. Double Emulsion and Evaporation Method: The 
emulsion and evaporation method which involves the 
addition of aqueous drug solutions into organic polymer 
solution under vigorous stirring to form w/o emulsions.  
Prepared w/o emulsion is then added into second aqueous 
phase with continuous stirring which form the w/o/w 
emulsion. This emulsion is subjected to solvent removal 
process by evaporation. Nanoparticles can be isolated by 
centrifugation at high speed. The prepared nanoparticles 
must be thoroughly washed and lyophilize. 
 
3. Emulsions Diffusion Method: In this method 
encapsulating polymer is dissolved in a partially water 
miscible solvent and then these solvent is saturated with 
water. The polymer-water saturated solvent phase is 
emulsified in an aqueous solution which contain stabilizer, 
leading to solvent diffusion to the external phase and the 
formation of nanocapsules or nanospheres. 
 
4. Solvent Displacement method: In this method 
precipitation of a polymer from organic solution and the 
diffusion of the organic solvent in the aqueous medium in the 
presence or absence of surfactant. Drug, Polymers, and/or 
lipophilic surfactant are dissolved in a water miscible 
semipolar solvent such as ethanol, acetone. The solution is 
then injected or poured into an aqueous solution under 
magnetic stirring. Nanoparticles prepared instantaneously 
by the rapid solvent diffusion. Then the solvent is removing 
from the suspension under reduced pressure.  
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5. Reverse Micelles: Reverse micelles are mixtures of water, 
oil and surfactant which are thermodynamically stable and 
shows a dynamic behaviour. The structure of reverse 
micelles consists of aqueous and oil volumes which are 
separated by surfactant films, as the observer zooms out to a 
more macroscopic scale reverse micelles appear 
homogeneous and isotropic. This advantage of reverse 
micellar formation is that ultrafine polymeric nanoparticles 
with narrow size distributions are produced, while applying 
traditional emulsion polymerization method larger 
nanoparticles (>200nm) will form with broad size 
distribution. The reverse micelle aqueous core acts as a Nano 
reactor in preparation of ultrafine nanoparticles.  
 
6. Ionotropic Gelation: In this process in which 
polyelectrolyte is cross-linked with a counter ion which 
forms a hydrogel. The structures of hydrogels are 
maintained by hydrogen bonding, hydrophobic forces, ionic 
forces or molecular entanglements. This technique has been 
applied using a variety of materials, including gellan gums, 
alginates, carboxymethyl cellulose and chitosan, to create 
micro and nanoparticles for encapsulation and controlled 
release of therapeutic agents.  
 
Depending on the material used, the strength of the counter 
ion and the desired particle size several methods of 
ionotropic gelation can be applied, including syringe 
dropping and air atomization for bead formation, and flush 
mixing for nanoparticles formation. 
ABSORPTION MECHANISMS OF NANOPARTICLE 
DELIVERY SYSTEMS 
The intestinal epithelium controls the passage of drugs, 
macromolecules, and particles. The surface area of the small 
intestine is enlarged because of the villi and microvilli which 
have a vital role in drug absorption in the gastrointestinal 
tract. The mechanisms of translocation of nanoparticles and 
micelles in the intestinal epithelium involve paracellular 
and/ or transcellular transport 29, 30 Paracellular pathway. 
The paracellular pathway is the preferred route for the 
transport of hydrophilic drugs. However, it restricts the 
passage of macromolecules or particles larger than 
approximately 1 nm because of a very small intercellular 
space and because of the tight junctions between the 
epithelial cells (pore diameter, 3e10 A°)[30]. Therefore, 
polymeric nanoparticles usually cannot pass through the 
intestinal barrier via the paracellular route. To improve their 
paracellular transport, the tight junction must be opened 
reversibly by using permeation enhancers such as cationic 
polymers (e.g., chitosan and its derivatives), anionic 
polymers (e.g., Polyacrylic acid and its derivatives), or 
calcium chelators (e.g., ethylene diamine tetra acetic acid). 
The width of the tight junction opened by the enhancers is < 
20 nm, which still limits the transport of intact nanoparticles 
into the bloodstream if the nanoparticle is > 20 nm 31. In this 
situation, the nanoparticles must be destabilized and 
disintegrated in the intercellular space when approaching 
the tight junction between the epithelial cells so that the 
loaded drug is released and permeated through the opened 
paracellular pathway.  
BIOAVAILABILITY OF ERYTHROPOIETIN-LOADED 
NANOPARTICLES 
The effectiveness and safety of erythropoietin nanoparticles 
have been assessed for their bioavailability, physiological 
response, therapeutic effect, and cytotoxicity. Venkatesan et 
al. prepared liquid-filled nanoparticles by using solid 
adsorbents such as carbon nanohorns and carbon 
nanotubes32. They found that liquid-filled erythropoietin 
carbon nanotubes improved the bioavailability of 
erythropoietin to 11.5% following invasive intra-small 
intestinal administration to rats. Bahgat E. Fayed et.al was 
loaded EPO in poly lactic-co glycolic acid (PLGA) 
nanoparticles which successfully altered the in vivo release 
profile and activity, allowing for more than 2-week activity 
after single injection using only double the EPO dose.33 Thus 
due to entrapment of polypeptide drug in nanoparticles, the 
half-life of the drug may be increased and reduces the side-
effects compared to conventional parenteral preparation. 
Thus the bioavailability of protein drug may improve with 
nanoparticulate technology. 
CONCLUSION AND FUTURE PERSPECTIVE 
It is very clear that the loading of EPO in nanoparticles 
successfully altered the in vivo release profile and activity, 
allowing for more than 2 week activity after single dose.  
Bahgat E. Fayed et.al was found that EPO in poly lactic-co 
glycolic acid (PLGA) nanoparticles improve release profile 
and activity, allowing for more than 2-week activity after 
single injection and reduces side effect due to drug 
accumulation32. Study found that in the treatment of anemia, 
hypoxia and in a newborn rat model, the effect of 
erythropoietin nanoparticles is 10 times greater than the 
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regular parenteral erythropoietin treatment34 Cody Bulmer 
prepared the erythropoietin nanoparticles and showed 30% 
release of encapsulated erythropoietin in 24 h and 68% 
release in two weeks. These erythropoietin release results 
can be used as a basis for more research on the application of 
nanoparticles within animal models 35. These studies show 
that erythropoietin loaded in nanoparticles significantly 
enhance its therapeutic effects. Further studies into the 
effect of nanoparticle structure on the biological activity of 
rHu-EPO and in vivo release studies need to be performed in 
order determine the true potential of nanoparticulate 
delivery for rHu-EPO for controlled release. The loading of 
EPO in nanoparticles depends upon the pH, Stirring speed, 
nature of polymer and a procedure use for the preparation of 
nanoparticles. Erythropoietin is protein structure which 
requires minimum stress conditions during preparation of 
nanoparticles to avoid any stability alteration to structure of 
erythropoietin.  
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